High Platelet Reactivity on Clopidogrel Predicts Stent Thrombosis, Heart Attack, and Bleeding, Columbia University Study

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial was published online in The Lancet. The findings were first presented at last year's Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium.

Hey, check out all the engineering jobs. Post your resume today!

Back to news